Novo Nordisk (NVO.US) invests up to $2.1 billion to partner with Vivtex to develop next-generation oral weight loss drugs

LootboxPhobia · 2026-02-26T04:10:13+00:00

Novo Nordisk and American Vivtex reach a $2.1 billion partnership to jointly develop oral medications for the treatment of obesity and diabetes. Vivtex's innovative drug delivery platform improves biologic drug absorption through advanced technology, helping to convert injectable drugs into oral formulations.

LootboxPhobia

2026-02-26 04:10:13

Abstract generation in progress

Reuters Finance APP has learned that Danish pharmaceutical company Novo Nordisk (NVO.US) announced on Wednesday that it has reached a partnership agreement worth up to $2.1 billion with U.S.-based Vivtex to jointly develop next-generation oral medications for the treatment of obesity and diabetes.

Under this collaboration, the private company will license some of its oral drug delivery technologies, while Novo Nordisk will be responsible for global development and commercialization.

It is understood that the core value of this partnership lies in Vivtex’s disruptive oral drug delivery platform. Developed with the involvement of renowned MIT scientist and Moderna co-founder Robert Langer and his team, the platform integrates advanced gastrointestinal chip models, high-throughput automated robotic screening, and artificial intelligence prediction algorithms.

With this system, the research team can simulate the absorption process of drugs in the human gut at unprecedented speed, accurately identifying the optimal formulations that significantly improve bioavailability from thousands of complex recipe combinations, thus overcoming the long-standing intestinal absorption barrier for peptides and proteins.

Here are some details:

According to the agreement, Novo Nordisk will pay an undisclosed upfront payment, milestone payments, and royalties on future product sales.

The collaboration aims to improve the absorption of biologic drugs in the gut, enabling biologics that traditionally require injections to be formulated as oral medications.

Both companies stated that Vivtex’s platform, utilizing intestinal screening, delivery technology, and AI tools, will help biologic drugs achieve tablet form.

Currently, Novo Nordisk offers GLP-1 drugs for obesity and type 2 diabetes, including Wegovy, Ozempic, and the oral diabetes medication Rybelsus.

In January this year, the Danish pharmaceutical company launched Wegovy tablets in the U.S., the world’s first oral drug for obesity treatment.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.